Recent News

• 12.08.2025 - Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
• 11.07.2025 - Exicure, Inc. Reports Third Quarter 2025 Financial Results
• 11.03.2025 - New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
• 10.06.2025 - Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Recent Filings

• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 8-K Current report
• 11.10.2025 - 8-K Current report
• 11.07.2025 - 8-K Current report
• 11.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.07.2025 - EX-99.1 EX-99.1
• 09.29.2025 - 3 Initial statement of beneficial ownership of securities
• 09.29.2025 - 3 Initial statement of beneficial ownership of securities
• 09.23.2025 - DEF 14A Other definitive proxy statements
• 09.22.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership